Lepu medical blockchain

1. This year, almost all the world has been swept over by COVID-19, and the economies of various countries have been more or less affected. In addition, the epidemic has rebounded in the winter, and the global situation is relatively turbulent. At this time, the State encourages people to reserve emergency medical supplies, which is not only to prepare for the next long-term epidemic prevention, but also to stimulate the consumer market and provide vitality for economic supply and demand

seeing this business opportunity, Lepu medical launched three first-aid kits, which is a normal business operation. In addition, epidemic prevention kits, home kits and disaster kits are indeed just needed procts in many scenarios. In addition, this year's medical information is full of people's attention, which will indirectly increase people's demand for medical emergency supplies. But guessing is always guessing. Next, we need to see the real market demand of this kind of emergency medical materials in practice

2. The future development of the company is estimated to be very good. The national policy now supports the development of household medical devices, and this plate is also the key development plate of Lepu, occupying the right time and place, so the future development will certainly not be bad.

3. Medical device / medicine / medical testing

4. Up channel, continue to hold. There is pressure above 60 yuan< br />

5. The procts of Lepu technology include POCT bedside diagnosis series of cardiac markers, CFMS xifens coagulation test series and molecular diagnosis series of cardiovascular disease under research. We have successfully established a variety of professional technology platforms, such as nano immunity, fluorescence detection, microfluidic, chemiluminescence, monoclonal antibody preparation and so on. Using advanced technology, the company has developed a new generation of POCT immunoquantitative analyzer and supporting reagents, which are well received in the domestic market and exported to more than ten countries such as Europe, Asia and Latin America. At present, the company is the first domestic enterprise to independently develop coagulation fibrinolysis panoramic analysis equipment, CFMS xifensi thromboelastography and related reagents can be regarded as the national brand of coagulation testing, breaking the monopoly of European and American procts at one stroke and filling the domestic blank; And molecular diagnosis technology makes Lepu technology walk in the forefront of the high-end market in the field of testing.

6. The CSRC has revealed that the 28 enterprises listed in the first batch all meet the requirements of the SME board.
it chose to be listed on the gem because they were listed earlier and got financing earlier.
at present, hundreds of companies have applied for listing on the SME board

7. It is not a foreign enterprise, but a domestic brand. It was established in 1999 and has been established for 20 years. Now it has become the leader in the domestic medical device instry.

8. Lepu intelligent is a subsidiary of Lepu medical

9. It's the right person to ask me, because a few days ago, I got to know this company on daily TV. The main procts of his family are: new Shuaike medicine, vascular stent, angiograph, etc.